BioCentury
ARTICLE | Deals

Dec. 7 Quick Takes: Sino pays $515M for Sinovac stake; plus BioCryst, Roivant, AbCellera, Syros, YZY, Maze 

December 8, 2020 2:33 AM UTC

Sino Biopharm buys $515M stake in Sinovac
Sino Biopharmaceutical Ltd. (HKEX:1177) paid $515 million for a 15% stake in Sinovac Biotech Ltd. (NASDAQ:SVA). The proceeds will fund development and production capacity expansion for Sinovac's Phase III-stage inactivated virus vaccine, CoronaVac, plus other development and operational activities.

BioCryst raises $325M to support Orladeyo launch, factor D inhibitor
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) raised a total of $325 million via a $125 million upfront payment from Royalty Pharma plc (NASDAQ:RPRX) for limited royalty rights to sales of Orladeyo berotralstat, and $200 million in credit from Athyrium Capital Management LP, $125 million of which BioCryst will withdraw at closing. The funds will support the launch of once-daily Orladeyo, the first orally administered non-steroidal option for preventing hereditary angioedema (HAE) attacks, and development of factor D inhibitor BCX9930, which is in Phase I testing for paroxysmal nocturnal hemoglobinuria (PNH)...